Monthly Archives: June 2012

BIO 2012: The Case for Collaboration

By Ben Comer | Published: June 19, 2012
Rodney King died on Sunday, but his famous question lives on: “Can we all get along?” At BIO 2012, the proposition seems to be: “Can we all just collaborate?”
Posted in Biotech, Europe, Events, FDA, Global, IP, People, R&D, Regulatory, Strategy, Technology, healthcare, leadership | Tagged , , , , , , , | Leave a comment

The Cost of Pharma Divorce

By Guest Blogger | Published: June 17, 2012
Final: THE COST OF PHARMA DIVORCE Corporate spin-offs are on the rise across the pharmaceutical sector, but at what cost to shareholders? Brian McGilligan, AVP, Life Sciences Program Management Consulting Lead at Cognizant argues that in haste to obtain decree absolute, demerging businesses could be threatening their long term viability. Demergers are in fashion again. After years of [...]
Posted in Deals, Global, Guest Blog | Tagged , , | 1 Comment

Meaningful Uses of HIT?

By Ben Comer | Published: June 15, 2012
A diverse group of HIT professionals – including physicians, academics, developers and entrepreneurs – gathered at Sudler & Hennessey’s Health and Technology Summit in New York City to discuss the challenges related to health information technology implementation, and the ways to move forward.
Posted in Strategy | Tagged , , , , , , | Leave a comment

Cause and Effect—Sales Rep Visits and Physician Prescribing Habits

By Jennifer Ringler | Published: June 11, 2012
A new study suggests that physicians who see fewer reps are slower when it comes to dropping ‘black-box’ drugs—and at adopting promising new medications. If you’ve ever had any doubts about whether your sales reps are actually affecting the prescribing habits of the physicians they visit, a new report by ZS Associates, recently reported on in [...]
Posted in Marketing, Sales, healthcare | Tagged , , , | 1 Comment

Fixing Innovation: Lilly's CEO Says Why, and How

By Ben Comer | Published: June 11, 2012
Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
Posted in Europe, Events, FDA, Global, IP, Legal, Market Access, Meetings, People, R&D, Regulatory, Safety, Strategy, Technology, healthcare, leadership, pricing | Tagged , , , , , , , , , , , , , | 1 Comment